ADIPOQ and metabolic dysfunction-associated steatotic liver disease: In this study, adiponectin showed a similar performance to AFP (the latter considered to be a predictor of HCC [69]) for discriminating NAFLD patients with advanced fibrosis and HCC than those without HCC, independent of potential cofounders [68].